Perkin-Elmer

Perkin-Elmer

PerkinElmer, Inc.
Public
Traded as S&P 500 Component
Industry Human health, environmental analysis, medical imaging, drug discovery, diagnostics, biotechnology, specialty lighting and sensors
Founded 1931
Headquarters Waltham, Massachusetts, U.S.
Key people Robert Friel, Chairman, CEO, and President
Products Analytical instruments, genetic testing and diagnostic tools, medical imaging equipment, software, instruments and consumables for life sciences
Revenue $1.8 billion USD (2009)
Employees 8,800 (2010)
Website www.perkinelmer.com

PerkinElmer, Inc. is an American multinational technology corporation, focused in the business areas of human and environmental health, including environmental analysis, food and consumer product safety, medical imaging, drug discovery, diagnostics, biotechnology, industrial applications, and life science research. PerkinElmer produces analytical instruments, genetic testing and diagnostic tools, medical imaging components, software, instruments, and consumables for multiple end markets.

PerkinElmer is part of the S&P 500 index and operates in 150 countries. As of 2010, it has a market capitalization of ~3.0 billion USD.

History

PerkinElmer traces its history back to a merger between divisions of what had been two S&P 500 companies, EG&G Inc. (formerly Template:Nyse2) of Wellesley, Massachusetts and Perkin-Elmer (formerly Template:Nyse2) of Norwalk, Connecticut. On May 28, 1999, the non-government side of EG&G Inc. purchased the Analytical Instruments Division of Perkin-Elmer, its traditional business segment, for US$425 million, also assuming the Perkin-Elmer name and forming the new PerkinElmer company, with new officers and a new Board of Directors.[1][2] At the time, EG&G made products for diverse industries including automotive, medical, aerospace and photography.[2]

The old Perkin-Elmer Board of Directors and Officers remained at that reorganized company under its new name, PE Corporation. It had been the Life Sciences division of Perkin-Elmer, and its two component tracking stock business groups, Celera Genomics (Template:Nyse2) and PE Biosystems (formerly Template:Nyse2), were centrally involved in the highest profile biotechnology events of the decade, the intense race against the Human Genome Project consortium, which then resulted in the genomics segment of the technology bubble.

EG&G began in 1931; It was started by two MIT professors, Harold Edgerton and Kenneth Germeshausen in a Boston garage. The company was originally incorporated in 1947 as EG&G.

Perkin-Elmer was founded in 1937 by Richard Perkin and Charles Elmer as an optical design and consulting company. In 1944, Perkin-Elmer entered the analytical-instruments business, and in the early 1990s, partnered with Cetus Corporation (and later Hoffmann-La Roche) to pioneer the polymerase chain reaction (PCR) equipment industry. Analytical-instruments business was also operated from 1954 to 2001 in Germany, by the Bodenseewerk Perkin-Elmer GmbH located in Überlingen at Lake Constance, and England (Perkin Elmer Ltd) at Beaconsfield in Buckinghamshire.


KH-9 Hexagon

Perkin-Elmer built the optical systems for the KH-9 Hexagon series of spy satellites at a facility in Danbury, Connecticut.[3]

Hubble optics failure

Perkin-Elmer was commissioned to build the optical components of the Hubble Space Telescope. The construction of the main mirror was begun in 1979 and completed in 1981. The polishing process ran over budget and behind schedule, producing significant friction with NASA. Due to a miscalibrated null corrector, the primary mirror was also found to have a significant spherical aberration after reaching orbit on STS-31. A NASA investigation heavily criticized Perkin-Elmer for management failings, disregarding written quality guidelines, and ignoring test data that showed this miscalibration.[4] Corrective optics were installed on the telescope during the first Hubble service and repair mission STS-61. The correction, COSTAR, was applied entirely to the secondary mirror and replaced existing instrumentation: the primary mirror still has a significant aberration.

PerkinElmer today

In 1992 the company merged with Evotec, the former owner company. PerkinElmer had a license to use the brand till the end of year 2007.

PerkinElmer has continued to expand its interest in medicine with the acquisitions of clinical laboratories, In July 2006, it acquired ViaCord.

In March 2008, PerkinElmer purchased Pediatrix Screening (formerly Neo Gen Screening), a laboratory located in Bridgeville, PA specializing in screening newborns for various inborn errors of metabolism such as PerkinElmer Genetics, Inc.

In May 2011, PerkinElmer announced the signature of an agreement to acquire CambridgeSoft, and the successful acquisition of ArtusLabs.[5]

In September 2011, PerkinElmer bought Caliper Life Sciences for $600 million.[6]

Focus areas

  • Cellular research
  • Clinical genetics & diagnostics
  • Drug discovery
  • Environmental Analysis - Air, water, and soil testing and analysis
  • Food, Flavors & Agricultural Analysis - Food safety
  • Forensic analysis
  • Hydrocarbon processing
  • Life science research
  • Lubricants and oils
  • Imaging, lighting, sensors
  • Pharmaceutical development and manufacturing
  • Polymers
  • Semiconductors and electronics
  • Renewable Energy - Analysis and testing for biofuels, solar, and wind energy
  • Global Multivendor Laboratory Maintenance & Repair Services
  • Global Laboratory Relocation Services

See also

References

External links

  • PerkinElmer Corporate website
  • PerkinElmer Announces New Business Alignment Focused on Improving Human and Environmental Health
  • SEC filings for PerkinElmer, Inc.